Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARVEL-TTAS: Apixaban Therapy for Venous Thromboembolism Assessed by T-TAS
jRCTs071180059Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of apixaban in deep vein thrombosis (DVT), venous thromboembolism (VTE) and pulmonary embolism (PE), sponsored by Bristol Myers Squibb. Primary endpoint: Primary: Fluctuation of AR10-AUC30 with or without bleeding events. Started Sep 2019; status: completed.
02
Drugs
apixaban
03
Conditions
deep vein thrombosis (DVT)venous thromboembolism (VTE)pulmonary embolism (PE)
Beyond the preview
Go deeper on jRCTs071180059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180059.